ClinicalTrials.gg
CompletedNCT03319706Updated Oct 24, 2017

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablets Under Fed Conditions

A Phase 1 interventional study of Torrent's Olmesartan Medoxomil Tablets 40 mg and Daiichi Sankyo Inc's Benicar Tablets 40 mg in Healthy Subjects, sponsored by Torrent Pharmaceuticals Limited. Completed. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-24.

Sponsored by Torrent Pharmaceuticals Limited · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

Subjects to compare the single dose bioavailability of Torrent's Olmesartan Medoxomil Tablets 40 mg and Benicar® 40 mg Tablets of Daiichi Sankyo Inc., USA. Dosing periods of studies were separated by a washout period of 7 days.

Read the detailed description

An Open Label, Randomized, 2-period, 2- Treatment, 2-Sequence, Crossover, Single-dose Bioequivalence Study of Olmesartan Medoxomil Tablets containing Olmesartan Medoxomil 40 mg (Test Formulation, Torrent Pharmaceutical Ltd., India) Versus Benicar® 40 mg Tablets containing Olmesartan Medoxomil 40 mg (Reference, Daiichi Sankyo Inc., USA) in Healthy Human Volunteers Under Fed Condition.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Torrent Pharmaceuticals Limited is the lead sponsor of 72 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males with age between 18-45 years (both inclusive)
  • Weight equal to or more than 50.00 Kgs
  • 18.50 - 24.90 Kg/m2
  • Healthy as determined by medical history, clinical and laboratory examination performed within 21 days prior to admission day for the first period of the study.
  • Must have provided written for participation in the study in the subject's vernacular language
  • In the opinion of the Principal Investigator/Designee, be able to comply with the study procedures and protocol restrictions.

Exclusion criteria

Exclusion Criteria:

  • Known or idiosyncratic reaction to Olmesartan, its or similar classes of drugs
  • Any evidence of significant abnormalities upon physical or clinical examination
  • Sitting blood pressure less than 100/70 mm Hg or more than 140/90 mm Hg and radical pulse rate less than 60 mm Hg or more than 100 mm Hg per minute at the time of screening.
  • Laboratory values, which are significantly different from predefined reference ranges and judged .
  • Any clinically significant abnormality in .
  • Any clinically significant abnormality in Chest X-ray (PA view)
  • Regular use of tobacco or nicotine in significant amount in any form (e.g. use of more than 10 cigarettes a day) or have difficulty in abstaining from [smoking] nicotine use for the duration of the study period.
  • History of drug dependence or excessive alcohol intake [subjects who drink more than 2 units per day (30 ml of 40% alcohol) or more than 14 units per week] on a habitual basis, or inability to abstain from alcohol for the duration of study period.
  • History or presence of serious gastrointestinal, liver, kidney, heart, lung, neurological or blood disease, diabetes or glaucoma.
  • History or presence of any chronic illnesses such as arthritis, asthma, epilepsy, hypertension etc.
  • Presence of disease markers of 1 OR 2, or C Viruses and VDRL.
  • Positive result for drug(s) of abuse testing (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and opioids) in urine.
  • Positive test for alcohol breath analyzer test.
  • History and presence of any psychiatric illness.
  • History and presence of any illness including allergic skin diseases, allergic asthma and drug-induced allergy, e.g. NSAIDs
  • History of significant blood loss (≥ 350 mL) due to any reason, including blood donation within last 12 weeks prior to screening.
  • Existence of any surgical or medical condition which in the judgment of Principal Investigator/ Designee might interfere with the absorption, distribution, metabolism or excretion of the study drug, or, is likely to compromise the safety of subject.
  • Intake of any enzyme-modifying drugs such as cimetidine, theophylline, benzodiazepines, ranitidine, proton pump inhibitors, erythromycin, diuretics, ketoconazole, anti hypertensive drugs, dopamine agonists, etc within 30 days of study drug administration, or administration/ intake of any prescription or OTC drug including vitamins and natural supplements within 30 days of study drug administration. In such cases, enrolment of the subject in the study will be at the discretion of the Principal Investigator/designee.
  • Intake of unusual diet (e.g. low sodium) for two weeks prior to screening and throughout the subject's participation the study. In such case, subject selection will be at the discretion of the Principal investigator/ designee.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Test

    Torrent's Olmesartan Medoxomil Tablets 40 mg

    Drug: Torrent's Olmesartan Medoxomil Tablets 40 mg

  • Active comparator
    Reference

    Daiichi Sankyo Inc's Benicar Tablets 40 mg

    Drug: Daiichi Sankyo Inc's Benicar Tablets 40 mg

Interventions

  • DrugTorrent's Olmesartan Medoxomil Tablets 40 mg
  • DrugDaiichi Sankyo Inc's Benicar Tablets 40 mg
06

What researchers measure

Primary outcomes

  1. Cmax

    Time frame: pre-dose to 72 hours post dose

  2. AUC

    Time frame: pre-dose to 72 hours post dose

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2017
First posted
Oct 24, 2017
Start
Aug 2010
Primary completionActual
Sep 2010
CompletionActual
Sep 2010
Last update
Oct 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03319706
Responsible party
Sponsor
First posted
Oct 24, 2017
Start date
Aug 2010
Primary completion
Sep 2010
Completion
Sep 2010
Last update
Oct 24, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion